




FDA ADVISORY
No. **2023-0093**

09 JAN 2023

TO: THE GENERAL PUBLIC

SUBJECT: Public Health Warning Against the Purchase and Use of Unauthorized Cosmetic Product HP DERM REJUVENATING CREAM containing Banned Ingredient/s

The Food and Drug Administration (FDA) warns the public from purchasing and using the adulterated and unauthorized cosmetic product **HP DERM REJUVENATING CREAM** which tested positive for the presence of **TRETINOIN**. This ingredient is not allowed to be part of a cosmetic product as per Annex II Part 1 of the ASEAN Cosmetic Directive (ACD). As per Administrative Order No. 13 s. 1999, products containing Tretinoin (Retinoic Acid) is classified as home remedy, over-the-counter, or prescription drug. The table below indicates the particulars of the adulterated cosmetic product/s:

Product Details	Product Image/s
Name of Manufacturer/ Local Company Responsible for Placing the Product in the Market: Not Indicated	
Address: Not Indicated	
Country of Manufacture: Not Indicated	
Lot/Batch Number: HPDERM Manufacturing Date: JAN-2022 Expiration Date: JAN-2024	

The aforementioned adulterated and unauthorized cosmetic product is found to be non-compliant with existing standards, and thus pose potential hazards to the public. The use of adulterated cosmetic product may result to adverse reactions, including but not limited to, skin irritation, itchiness, anaphylactic shock and organ failure.




In light of the foregoing, the public is advised not to purchase the aforementioned adulterated cosmetic product. Always check if a product is notified with the FDA by using the FDA Verification Portal feature accessible at <https://verification.fda.gov.ph> which may be used by typing in the name of the product before the purchase and/or using the cosmetic products.

All concerned establishments are warned not to distribute violative cosmetic products.

All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of their jurisdiction.

To report any sale, distribution, complaint and/or adverse event on the use of the violative cosmetic product, the online reporting facility, eReport can be accessed at ereport@fda.gov.ph, or call us at the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research (CCHUHSRR) hotline **(02) 8857-1900 loc. 8107**.

Dissemination of this advisory to all concerned is hereby requested.


DR. SAMUEL A. ZACATE
Director General *4/06*

DTN: 20221229142259